ANTEOTECH LTD — Capital/Financing Update 2017

Jan 24, 2017

25 January 2017

==> picture [315 x 91] intentionally omitted <==

DIAsource and Future Diagnostics receive grant of 1.4m Euro to develop a CE marked unique Free Vitamin D assay for the IVD market.

• DIAsource and Future Diagnostics receive grant of 1.4m Euro from Eurostars (European Commission)

• Grant supports demonstration clinical utility and obtaining CE marking of the world's first assay to measure Free Vitamin D

DIAsource Immunoassays SA, part of the Anteo Group (ASX: ADO), and Future Diagnostics Solutions (the Netherlands) are pleased to announce that their Eurostars project application for the development of a Free 25OH Vitamin D assay for use in the IVD market has been successful, and that the project will receive €1.4m (AUD2m) in funding. A research-use-only assay has been developed and manufactured by Future Diagnostics using the proprietary DIAsource monoclonal antibodies and DIAsource received the exclusive worldwide distribution rights. The project was chosen from 331 eligible applications, and was further approved for funding by the national funding bodies of the project consortium.

The goal of the project is to develop a CE marked IVD immunoassay for the quantification of Free Vitamin D (25OHD) to assist in the reliable monitoring of patient Vitamin D status. This new assay will enable an optimized treatment of patients suffering from Vitamin D insufficiency thereby improving quality of life and generating significant cost-savings for society.

Anteo Group CEO Dr Jef Vangenechten said, “We are excited that we can continue the work on establishing a sound scientific basis for the importance and clinical utility of Free Vitamin D. With this support we can obtain CE marking and commercialise this unique assay in the clinical diagnostic testing market."

DIAsource currently sells this world’s first assay to measure Free Vitamin D as a research-use-only assay to the research community. Numerous recent studies suggest that the use of this assay to measure the free fraction of 25OH Vitamin D can be diagnostically more relevant in certain conditions like pregnancy, chronic kidney disease, liver failure, bladder and pancreatic cancer than measuring the total 25OH Vitamin D (as all other Vitamin D assays do). This project will allow further studies to be undertaken to demonstrate conclusively the clinical utility of this assay, to seek CE marking for the assay and to establish a clear positioning for this new marker prior to launching it in the global IVD Vitamin D market.

Eurostars is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. In the 2014-2020 period, it has a total public budget of €1.14 billion. Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&Dperforming SMEs). With its bottom-up approach, Eurostars supports the development of

==> picture [115 x 89] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==

==> picture [315 x 91] intentionally omitted <==

rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for highvalue commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 counties across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

==> picture [595 x 139] intentionally omitted <==